Study of NIO752 for progressive supranuclear palsy
Part of Brain & nervous system, Eyes & vision, Mental health clinical trials.
This trial tests a new medicine called NIO752 for people with progressive supranuclear palsy (PSP), a condition that affects movement, balance, and thinking. The goal is to see if it can help slow the disease's progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 41 and 81 years old.
- You have been diagnosed with probable or possible PSP (progressive supranuclear palsy) Richardson syndrome, and your symptoms started less than 5 years ago.
- You have a reliable study partner (like a spouse, family member, or close friend) who spends at least 5 hours per week with you and can come to study visits.
- You can walk at least 10 steps on your own or with just a little help (like holding one arm for balance).
- You do not have other significant neurological conditions (like Parkinson's disease, Alzheimer's disease, or a history of stroke).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called LM11A-31 to see if it can help people with progressive supranuclear palsy (PSP), a rare brain condition. You may join if you have had symptoms for 5 years or less, can walk with minimal help, and have good thinking abilities.
This trial tests potential new treatments for progressive supranuclear palsy (PSP), a brain disorder affecting movement, balance, and thinking. It aims to see if these treatments are safe and slow the disease. You may be able to join if you have a specific type of PSP and are in fairly good health.
This trial tests whether a supplement called nicotinamide riboside (NR) can help people with rare forms of parkinsonism (PSP, MSA, or CBS). It is a double-blind study, meaning neither you nor the doctors will know if you are getting the real supplement or a placebo.
This study tests an experimental drug called NIO752 to see if it can reduce the production of tau protein, which is linked to Alzheimer's disease. Researchers will measure how the drug affects tau in your body using a special technique called SILK.
This study tests a remote monitoring system to track symptoms of progressive supranuclear palsy (PSP) and similar movement disorders. It may tell you how your condition changes over time without needing frequent clinic visits.
This trial tests whether repeated non-invasive magnetic brain stimulation (TMS) can improve symptoms in people with progressive supranuclear palsy (PSP). It may help by targeting brain circuits involved in movement and balance.
Hear when a new Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.